Nine.com.au·4 min read·medium

TGA approves daily weight-loss pills in Australia: Wegovy and oral GLP-1s explained

T
Tilli Andrew
TGA approves daily weight-loss pills in Australia: Wegovy and oral GLP-1s explained
✦AI Summary

The Australian Therapeutic Goods Administration has approved two new oral weight-loss pills, Eli Lilly’s Foundayo and Novo Nordisk’s Wegovy. These non-injectable options aim to provide alternatives for patients managing weight and type 2 diabetes.

Why it matters

The approval of oral GLP-1 medications marks a significant shift in obesity treatment, potentially increasing accessibility for patients who are uncomfortable with injections.

✦Dive DeeperCreate a free account to unlock

- 9.42am . First published at 2.43am

shares Share article A second weight-loss pill has been approved for use in Australia , and could be available to patients in just days.

The Therapeutic Goods Administration (TGA) has cleared Eli Lilly’s Foundayo for weight management and type 2 diabetes, joining Novo Nordisk’s Wegovy tablet, which was also green-lit earlier this month.

A second weight-loss pill has been approved for use in Australia, expanding the non-injectable options available to patients. nna\josh.hohne

Lilly expects Foundayo stock to arrive within days, while Novo Nordisk says its pill should be available by the end of the year.

Both GLP-1 medicines require a prescription, though they differ in cost and dosing.

Lilly has indicated Foundayo will cost between $250 and $370 a month depending on the dose.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthsciencebusiness
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in